Struktur—Biomarker zur Früherkennung von Morbus Alzheimer

Alzheimer’s disease cannot be cured today. In addition to a drug, a predictive blood biomarker is urgently needed to identify high-risk subjects in early cognitively less impaired stages. Here, a biomarker is presented that uses the secondary structure distribution of Aβ-peptides in blood measured by the immuno-infrared sensor. Using this structure-based biomarker clinical conversion of symptomless subjects at baseline were predicted in a...